Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6364902 | 0.82 | CHRNA7 (0.44) | CHRNA7HTR3ACHRNA3LMNA | |
| SCHEMBL3984845 | 0.79 | L3MBTL1 (0.55) | CHRNA7HTR3ACHRNA3 | |
| SCHEMBL8635649 | 0.77 | PREP (0.45) | HCRTR2MEN1LMNAKMT2A | |
| SCHEMBL8636150 | 0.77 | ABL1 (0.43) | HCRTR2LMNA | |
| SCHEMBL6370229 | 0.71 | CHRNA7 (0.43) | CHRNA7HTR3AHCRTR2CHRNA3 | |
| SCHEMBL4628032 | 0.71 | POLB (0.53) | MEN1LMNAKMT2A | |
| SCHEMBL4702959 | 0.70 | SLC6A7 (0.54) | CHRNA7HTR3A | |
| SCHEMBL27271667 | 0.70 | ALDH1A1 (0.50) | MEN1LMNAKMT2A | |
| SCHEMBL4408507 | 0.69 | MAP2K1 (0.50) | CHRNA7HTR3AHCRTR2 | |
| SCHEMBL4700028 | 0.69 | GHSR (0.46) | CHRNA7HTR3ACHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239774-A1 | Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists | ASTRAZENECA AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239774-A1 | Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists | CHRNA1, CHRNB1, CHRNA2 | CHRNA7 6/4885HTR3A 162/4885HCRTR2 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.